Literature DB >> 16307738

Effects of fasudil, a Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats.

Seniz Demiryürek1, Ali F Kara, Ahmet Celik, Aydan Babül, Mehmet Tarakçioglu, Abdullah T Demiryürek.   

Abstract

The aim of this study was to examine the effects of fasudil, a Rho-kinase inhibitor, on ischemic preconditioning and carbachol preconditioning in anesthetized rats. The total number of ventricular ectopic beats was markedly augmented with fasudil at 0.3 mg/kg and depressed with fasudil at 10 mg/kg. Fasudil at 10 mg/kg also markedly decreased the ventricular tachycardia incidence. Ischemic preconditioning, induced by 5 min coronary artery occlusion and 5 min reperfusion, decreased the incidence of ventricular tachycardia and abolished the occurrence of ventricular fibrillation. The incidences of ventricular tachycardia and ventricular fibrillation in the fasudil (10 mg/kg) + ischemic preconditioning group were found to be similar to the ischemic preconditioning group. However, low doses of fasudil (0.3 and 1 mg/kg) appeared to prevent the antiarrhythmic effects of ischemic preconditioning. Carbachol (4 microg/kg/min for 5 min) induced marked reductions in mean arterial blood pressure, heart rate and abolished ventricular tachycardia. Marked reductions in ventricular ectopic beats and ventricular tachycardia were noted in the fasudil (10 mg/kg) + carbachol preconditioning group. Lactate levels were markedly reduced in the ischemic preconditioning group and this reduction was prominently inhibited with fasudil at 1 mg/kg. Ischemic preconditioning caused a marked decrease in plasma malondialdehyde levels. Fasudil (10 mg/kg), ischemic preconditioning and carbachol preconditioning each generated marked reductions in ischemic myocardial malondialdehyde levels. Decreases in infarct size were observed with fasudil (10 mg/kg) treatment, ischemic preconditioning and carbachol preconditioning when compared to control. These results suggest that low doses of fasudil (0.3 and 1 mg/kg) appeared to prevents the effects of ischemic preconditioning and carbachol preconditioning, but a high dose of fasudil (10 mg/kg) was able to produce cardioprotective effects on myocardium against arrhythmias, infarct size or biochemical parameters and mimic the effects of ischemic preconditioning in anesthetized rats.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307738     DOI: 10.1016/j.ejphar.2005.10.018

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

2.  ERK-MAPK signaling opposes rho-kinase to reduce cardiomyocyte apoptosis in heart ischemic preconditioning.

Authors:  Juan Zhang; Hong-Jun Bian; Xiao-Xing Li; Xiao-Bo Liu; Jun-Ping Sun; Na Li; Yun Zhang; Xiao-Ping Ji
Journal:  Mol Med       Date:  2010-03-17       Impact factor: 6.354

Review 3.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

4.  Rho-kinase inhibition is involved in the activation of PI3-kinase/Akt during ischemic-preconditioning-induced cardiomyocyte apoptosis.

Authors:  Juan Zhang; Xiao-Bo Liu; Chao Cheng; Dong-Ling Xu; Qing-Hua Lu; Xiao-Ping Ji
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 5.  RhoA/Rho-kinase and vascular diseases: what is the link?

Authors:  Kenia Pedrosa Nunes; Christine S Rigsby; R Clinton Webb
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

6.  Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.

Authors:  Claudia Mera; Iván Godoy; Renato Ramírez; Jackeline Moya; María Paz Ocaranza; Jorge E Jalil
Journal:  Ther Adv Cardiovasc Dis       Date:  2015-10-21

Review 7.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

8.  Investigation of leukocyte RHO/ROCK gene expressions in patients with non-valvular atrial fibrillation.

Authors:  Irfan V Düzen; Fethi Yavuz; Ertan Vuruskan; Erhan Saracoglu; Fatih Poyraz; Yusuf Cekici; Hayri Alıcı; Hüseyin Göksülük; Basar Candemir; Murat Sucu; Abdullah T Demiryürek
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

9.  Mechanism of H2S-mediated ROCK inhibition of total flavones of Rhododendra against myocardial ischemia injury.

Authors:  Yi Jiao; Ya-Nan Li; Zhi-Wu Chen; Yan Guo
Journal:  Exp Ther Med       Date:  2019-09-13       Impact factor: 2.447

10.  Rho-associated kinase activity is an independent predictor of cardiovascular events in acute coronary syndrome.

Authors:  Masato Kajikawa; Kensuke Noma; Ayumu Nakashima; Tatsuya Maruhashi; Yumiko Iwamoto; Takeshi Matsumoto; Akimichi Iwamoto; Nozomu Oda; Takayuki Hidaka; Yasuki Kihara; Yoshiki Aibara; Kazuaki Chayama; Shota Sasaki; Masaya Kato; Keigo Dote; Chikara Goto; James K Liao; Yukihito Higashi
Journal:  Hypertension       Date:  2015-08-17       Impact factor: 10.190

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.